60 Degrees Pharmaceuticals filings document a specialty pharmaceutical issuer with Nasdaq-listed common stock and warrants, emerging-growth-company status and a business focused on medicines for vector-borne disease. Its recent Form 8-K disclosures record material events involving the company’s at-the-market equity offering program, related legal opinions, beneficial-ownership corrections, investor-presentation materials, and clinical development and regulatory strategy updates.
The filing record also covers capital-structure and governance matters, including a one-for-four reverse stock split approved through amendments to the certificate of incorporation, annual meeting voting results and Nasdaq listing-compliance notices. These disclosures frame the company’s formal reporting around ARAKODA, tafenoquine development, equity financing mechanics, security-holder votes and exchange-related requirements.
60 Degrees Pharmaceuticals, Inc. filed a Form 8-K to note that it obtained and filed an updated legal opinion from its counsel covering shares of common stock issued and sold under its existing at-the-market equity offering program with HC Wainwright & Co., LLC.
The company states that this opinion does not change the terms of the at-the-market program. Instead, it confirms the validity of shares that may be sold under the program and addresses certain legal matters related to those sales under applicable law.
60 Degrees Pharmaceuticals, Inc. amends its at-the-market program to permit the offer and sale of up to $981,000 of common stock pursuant to the Sales Agreement with H.C. Wainwright & Co., LLC, March 11, 2026.
The $981,000 capacity reflects and includes 566,067 shares previously sold for aggregate gross proceeds of $1,307,508.15 under the Sales Agreement. The company reports a public float of $11,056,547 based on 2,147,749 outstanding shares, of which 2,126,259 were held by non-affiliates as of January 28, 2026. The company effected a one-for-four reverse stock split on January 20, 2026.
60 Degrees Pharmaceuticals amends its at-the-market program to register up to $1,308,000 of common stock pursuant to its September 5, 2025 Sales Agreement with H.C. Wainwright & Co., LLC.
The prospectus supplement updates the aggregate offering capacity to $1,308,000, excluding 555,593 shares previously sold for aggregate gross proceeds of $1,396,091. It states a public float of approximately $8,112,998 based on 1,581,682 shares outstanding as of January 28, 2026 and notes a one-for-four reverse stock split effective January 20, 2026. The filing cites the Form S-3 limitation that sales will not exceed one-third of public float in a 12-month period.
60 Degrees Pharmaceuticals, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price requirement of $1.00 per share under Listing Rule 5550(a)(2). Nasdaq’s Listing Qualifications Staff confirmed the company now meets all Nasdaq Capital Market listing standards.
The company had previously received a delisting notice after its stock traded below $1.00 for 30 consecutive business days and paid a $20,000 hearing fee to appeal. With compliance restored, the February 19, 2026 Nasdaq Hearings Panel session has been cancelled, the delisting matter is closed, and the company’s common stock and warrants will continue to trade on The Nasdaq Capital Market.
60 Degrees Pharmaceuticals, Inc. (SXTP) reports that Nasdaq staff has determined to delist its common stock and warrants from The Nasdaq Capital Market. Nasdaq concluded the company failed to maintain the required minimum bid price of $1.00 per share for 30 consecutive business days under Listing Rule 5550(a)(2), and that it is not eligible for the usual 180‑day grace period because it completed a 1‑for‑5 reverse stock split on February 24, 2025 under Listing Rule 5810(c)(3)(A)(iv). The company’s warrants are also subject to delisting under Listing Rule 5560(a) because the underlying common stock is subject to delisting. The company has paid a $20,000 hearing fee and requested an appeal to a Nasdaq hearings panel, which temporarily stays any trading suspension and the filing of a Form 25‑NSE until the panel issues its decision.
60 Degrees Pharmaceuticals, Inc. approved a reverse stock split of its common stock at a final ratio of one-for-four. The company’s stockholders approved the amendment to its Certificate of Incorporation on October 8, 2025, after a recommendation from the board of directors. The company then filed a Certificate of Amendment in Delaware on January 14, 2026, which becomes effective at 12:01 a.m. Eastern Time on January 20, 2026.
At the effective time, every four shares of issued and outstanding common stock are automatically combined and converted into one share. The company is not issuing fractional shares; any fractional amounts are rounded up to one whole share. The company also issued a press release about the reverse split on January 15, 2026, which is included as an exhibit.
60 Degrees Pharmaceuticals, Inc. reported that on January 8, 2026 it made a new investor presentation available in connection with a webinar hosted by RedChip Companies, Inc. The presentation, furnished as Exhibit 99.1, provides updated information on the company’s clinical development timelines and regulatory strategy.
The materials are provided under Regulation FD and are stated as being furnished rather than filed, meaning they are not automatically incorporated into other securities law reports. The company notes that the presentation contains forward-looking statements and cautions that actual results may differ due to various risks and uncertainties.
60 Degrees Pharmaceuticals reported that President and CEO Geoffrey Dow, who is also a director, bought 9,670 shares of its common stock on December 15, 2025 at $0.8024 per share. Following this purchase, he directly owns 59,618 common shares of the company.
60 Degrees Pharmaceuticals President and CEO Geoffrey Dow, who also serves as a director, reported buying additional common stock in December 2025. He acquired 9,350 shares on 12/10/2025 at $0.9504 per share and 3,613 shares on 12/11/2025 at $0.9184 per share. After these transactions, he directly owned 49,948 common shares of the company.
60 Degrees Pharmaceuticals (SXTP) reported Q3 2025 results. Cash and cash equivalents were $4,115,779 as of September 30, 2025, up from $1,659,353 at year‑end, primarily reflecting equity financings completed in January, February, and July. Product revenue was $437,602, up from $135,293 a year ago, while research revenue was $90,960. The quarter’s net loss attributed to the company was $2,316,324, and net loss attributed to common stockholders was $2,443,191, or $0.66 per share.
Operating expenses totaled $2,316,397, including research and development of $809,777 and general and administrative of $1,506,620. An inventory reserve drove a cost of revenues increase and a gross loss of $100,088; the company recorded $436,561 of write‑downs for expired inventory in the quarter. Derivative liabilities measured at fair value were $797,275 among current liabilities totaling $2,197,394.
The company disclosed substantial doubt about its ability to continue as a going concern, citing accumulated losses and cash used in operations of $5,156,566 for the nine months. Common shares outstanding were 4,104,469 at quarter‑end and 4,230,448 as of November 13, 2025. During 2025, it raised net proceeds of $804,346, $908,627, and $4,281,300 through registered offerings, and established a $1,397,532 ATM program with no sales as of quarter‑end.